Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0S0MP
|
|||
Former ID |
DIB001746
|
|||
Drug Name |
SGN-30
|
|||
Drug Type |
Antibody
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Lymphocyte activation antigen CD30 (TNFRSF8) | Target Info | . | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
NetPath Pathway | Leptin Signaling Pathway | |||
TCR Signaling Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT00099255) Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma. U.S. National Institutes of Health. | |||
REF 2 | The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. 2002 Jul 1;62(13):3736-42. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.